RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.9006
-0.0094 (-1.0330%)
As of 2:36PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.9100
Open0.9100
Bid0.9003 x 500
Ask0.9039 x 100
Day's Range0.8912 - 0.9564
52 Week Range0.7900 - 2.7500
Volume391,511
Avg. Volume710,037
Market Cap93.622M
Beta0.86
PE Ratio (TTM)N/A
EPS (TTM)-1.2420
Earnings DateFeb 28, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT

    Q3 2017 Regulus Therapeutics Inc Earnings Call

  • Associated Presslast month

    Regulus reports 3Q loss

    The San Diego-based company said it had a loss of 18 cents per share. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also ...

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks2 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

  • Regulus to Present at the 2017 Wells Fargo Healthcare Conference
    PR Newswire3 months ago

    Regulus to Present at the 2017 Wells Fargo Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
    Zacks4 months ago

    Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

    Investors in Regulus Therapeutics Inc. (RGLS) need to pay close attention to the stock based on moves in the options market lately.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT

    Q2 2017 Regulus Therapeutics Inc Earnings Call

  • Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
    PR Newswire4 months ago

    Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Associated Press4 months ago

    Regulus reports 2Q loss

    The San Diego-based company said it had a loss of 41 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • Regulus Reports Second Quarter 2017 Financial Results and Recent Events
    PR Newswire4 months ago

    Regulus Reports Second Quarter 2017 Financial Results and Recent Events

    Completed Public Offering Raising $46 Million in Gross Proceeds Conference Call Today at 5:00 p.m. ET LA JOLLA, Calif. , Aug. 1, 2017 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical ...

  • ACCESSWIRE4 months ago

    Investor Network: Regulus Therapeutics Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 1, 2017 / Regulus Therapeutics Inc. (NASDAQ: RGLS ) will be discussing their earnings results in their Q2 Earnings Call to be held August 1, 2017 at 5:00 PM Eastern Time. ...

  • GuruFocus.com5 months ago

    Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares

    President and CEO of Regulus Therapeutics Inc (NASDAQ:RGLS) Joseph P Hagan bought 219,780 shares of RGLS on 07/25/2017 at an average price of $0.91 a share.

  • Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
    PR Newswire5 months ago

    Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

    Regulus is a biopharmaceutical company developing innovative medicines targeting microRNAs.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.  Regulus maintains its corporate headquarters in La Jolla, CA. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements include, without limitation, statements regarding the amount of net proceeds from the offering, the intended use of proceeds from the offering and the expected ability of Regulus to undertake certain activities and accomplish certain goals with respect to its development programs.

  • Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017
    PR Newswire5 months ago

    Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017

    Regulus will host a conference call and webcast on August 1, 2017 at 5:00 p.m. Eastern Time to discuss second quarter 2017 financial results and corporate highlights. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 57973022. Regulus Therapeutics Inc. (RGLS) is a clinical stage biopharmaceutical company focused on discovering and developing first-in-class drugs targeting microRNAs to treat diseases with significant unmet medical need. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.

  • Regulus Announces Pricing of Public Offering of Common Stock
    PR Newswire5 months ago

    Regulus Announces Pricing of Public Offering of Common Stock

    LA JOLLA, Calif., July 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at the price to the public of $0.91 per share.  Regulus has granted the underwriters a 30-day option to purchase up to an additional 6,600,000 shares of common stock. The net proceeds to Regulus from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $37.3 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus.  Regulus intends to use the net proceeds from the offering to fund clinical development of its clinical candidates, RG-012 and RGLS4326, development of its earlier microRNA development candidates and programs, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes.

  • Regulus Announces Commencement of Public Offering of Common Stock
    PR Newswire5 months ago

    Regulus Announces Commencement of Public Offering of Common Stock

    LA JOLLA, Calif. , July 19, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced that it has commenced ...

  • SmarterAnalyst6 months ago

    Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations

    Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a miR-122 inhibitor for the treatment of hepatitis C, RG-125, a miR-103/107 inhibitor for the treatment of non-alcoholic steatohepatitis, and RGLS5040, a miR-27 inhibitor for the treatment for cholestatic disorders. In the wake of the clinical updates, Chardan analyst Madhu Kumar slashed his price target to $5.00 (from $2.50), while reiterating a Buy rating on the stock. To the company’s credit, the analyst points out that the company's lead drug RG-012, a miR-21 inhibitor for the treatment of Alport syndrome, is still on the run and has a “favorable risk-benefit profile." Kumar reminds “The phase II HERA trial is expected to provide renal biopsy data by year end-2017 and interim efficacy data by mid-2018,” and highlights the drug maker’s future is strongly linked to RG-012 performance.

  • TheStreet.com6 months ago

    Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

    After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

  • Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
    PR Newswire6 months ago

    Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer

    LA JOLLA, Calif., June 13, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promotion of Dr. Mark Deeg to Chief Medical Officer. Dr. Deeg joined Regulus in April 2017 as Vice President of Translational Medicine. In his new role, he will lead the Company's clinical development teams in addition to his oversight of translational medicine.

  • Regulus Announces Pipeline Updates and Advancements
    PR Newswire6 months ago

    Regulus Announces Pipeline Updates and Advancements

    "We are squarely focused on taking the steps necessary to advance our pipeline and continue building shareholder value. To that end, we recognize that we must be disciplined in our investment choices and focus our resources and capital on our most promising discovery and development programs, including the application of important development, regulatory and commercial considerations," said Jay Hagan, President and Chief Executive Officer of Regulus. RG-012 for Alport syndrome: Initiation of the Phase II clinical programs for RG-012 for the treatment of Alport syndrome is on track as planned. Important changes to the Phase II study design have been incorporated with the goal to accelerate patient enrollment, improve statistical power, and potentially achieve proof of mechanism data by the end of 2017. HERA, the Phase II randomized (1:1), double-blinded, placebo-controlled study evaluating the safety and efficacy of RG-012 in Alport syndrome patients, has been modified to increase enrollment to 40 patients to improve its statistical power.

  • PR Newswire6 months ago

    Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics

    GREENWICH, Connecticut, June 8, 2017 /PRNewswire/ -- Provides range of discovery, CMC and non-clinical services Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between ...

  • Pascale Witz Joins Regulus Board of Directors
    PR Newswire6 months ago

    Pascale Witz Joins Regulus Board of Directors

    LA JOLLA, Calif., June 1, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced Pascale Witz was elected to the Company's board of directors at its Annual Meeting of Stockholders held earlier today.

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT

    Q1 2017 Regulus Therapeutics Inc Earnings Call

  • Accesswire7 months ago

    Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down

    NEW YORK, NY / ACCESSWIRE / May 8, 2017 / Regulus Therapeutics may not have delivered an impressive first quarter report but shares soared anyway after a change in directors took place. Corvus Pharmaceuticals ...

  • Associated Press7 months ago

    Regulus reports 1Q loss

    The San Diego-based company said it had a loss of 38 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...

  • Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring
    PR Newswire7 months ago

    Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring

    LA JOLLA, Calif., May 4, 2017 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today ...